Healthcare

Strong diagnostic trial results and regulatory recognition have put Clarity among the ASX healthcare names investors are watching closely.

Fast test-volume growth and an expanding product pipeline have framed the question of whether the next commercial catalyst could spark a re-rating.

A fundedBalance Sheetand a schedule of clinical readouts have framed the question of whether the market is underestimating this healthcare growth story.

The progress of its pivotal Phase 3 trial and its partnering activity have framed the question of whether the next catalyst could spark a major re-rating.

A shift toward higher-value recurring revenue, set against a declining reported top line, has framed the question of whether the next commercial catalyst could spark a re-rating.

Record FY26 revenue and a sharp profit increase have raised the question of whether the market is underestimating this healthcare growth story.

The launch of CORIS and the trajectory of the trophonBusinesshave framed the question of whether the next catalyst could spark a major re-rating.